The article you requested is
ASCP Corner: Second-Generation Antipsychotic-Associated Diabetes Mellitus and Diabetic Ketoacidosis: Mechanisms, Predictors, and Screening Need (ASCP Corner).
J Clin Psychiatry 2009;70(5):765-766
Copyright 2009 Physicians Postgraduate Press, Inc.
To view this item, select one of the options below.
Purchase this PDF for $40
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP print + online for $166 individual.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send an email
Antipsychotic medications, as well as schizophrenia, have been
associated with an increased risk for diabetes. However, the
relative contributions of the underlying illness, unhealthy lifestyle
behaviors, and medications used to treat schizophrenia are
still unclear. Although first- and second-generation antipsychotics
have been contrasted broadly in the literature regarding their
risks for glucoregulatory abnormalities, there is now sufficient
evidence to suggest that the risk for diabetes is not uniform
within each antipsychotic class.